COI
PBE icon

Capital One Investing’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Capital One Investing’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$707K Sell
14,909
-300
-2% -$15.4K 0.16% 98
2019
Q2 		$814K Sell
15,209
-50
-0.3% -$2.59K 0.2% 82
2019
Q1 		$843K Sell
15,259
-150
-1% -$7.93K 0.22% 76
2018
Q4 		$725K Buy
+15,409
New +$792K 0.26% 64

Other funds holding PBE

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PA
PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

Capital One Investing's PBE Position: Q3 2019 in Review

Capital One Investing reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 2% in Q3 2019, selling an estimated $15.4K and leaving 14,909 shares worth $707K. The position accounts for 0.16% of the portfolio, ranked #98.

Capital One Investing first reported a position in PBE in Q4 2018 and has held it in 4 quarters since. The position peaked at $843K in Q1 2019. 73 funds tracked by Wall St. Rank hold PBE as of Q3 2019.

  • Capital One Investing held 14,909 shares of Invesco Biotechnology & Genome ETF worth $707K as of Q3 2019.
  • Capital One Investing sold 300 Invesco Biotechnology & Genome ETF shares in Q3 2019, an estimated $15.4K.
  • Invesco Biotechnology & Genome ETF made up 0.16% of Capital One Investing's portfolio in Q3 2019, its #98 holding.
  • Capital One Investing first reported a position in Invesco Biotechnology & Genome ETF in Q4 2018 and has held it in 4 quarters since.
  • Capital One Investing's Invesco Biotechnology & Genome ETF position peaked at $843K in Q1 2019.
  • 73 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2019.

Based on Capital One Investing's 13F filing for Q3 2019, filed 14 Nov 2019.